Latest Conference Articles

Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.

The phase 3 data presented at the ISTH 2022 Annual Congress show an 86% reduction of treated bleeds in patients with hemophilia A or B with inhibitors.

Real-world patients showed improvement in visual acuity and anatomic parameters, but are still at an early time point in TRUCKEE study.

Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.

Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.

The best overall outcomes were attained in eyes without fluid and ellipsoid zone integrity preservation, investigators said.

Travis Vandergriff, MD, discusses the unique collaboration with ophthalmologists and urologists in the rare skin condition.

An analysis of PSOARING 1 and 2 data show the topical therapy is efficacious across a wide spectrum of psoriatic disease and patient demographics.

An analysis suggests patients on the biologic fared better with adherence and outcomes than those on competitors including adalimumab.

At HiD 2022, Dr. Budoff discusses the use and utility of coronary calcium scoring for risk stratification

Dr. Martin explores the explosion of new consumer technologies and how to close the gap in disparities between data collection and using the data in practice.

Dr. Ray discusses the impact of current practice on cholesterol goal attainment and what more needs to be done.

Dr. Green discusses the potential of combination therapy to reduce cardiovascular and kidney outcomes in people with type 2 diabetes.

Dr. Joseph discusses modalities to address cardiometabolic disease in individuals around the country, from lifestyle management to policy-level changes.

New phase 3 data show a microencapsulated form of the topical antiseptic and vitamin D derivative is beneficial and tolerable over 12 weeks.

Savanna Perry, PA-C, discussed the challenge of standing out over influencers and estheticians regarding clinical dermatology insight, and the unique offerings of different platforms.

New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.

Investigators presented the study at the Netherlands Ophthalmological Society Annual Congress, noting a potential cause for this trend could be the heightened cautiousness of surgical teams following the 2 month intermission due to the COVID-19 pandemic.

Results from a cross-sectional survey suggest consistent patient preferences for treatment outcomes and means of administration.

Savanna Perry, PA-C, founder of The PA Platform, discusses the strategies and goals that go into building an online audience as a healthcare professional.

New phase 3 extension data show the topical PDE-4 inhibitor provided skin clearance to a significant rate of patients with psoriasis.

A team of investigators observe notably improved health care cost savings among patients who initiated care more than a year prior to those who haven't at all.

While there's evidence that blue light exposure can impact an individual's circadian system, Dr. Aric Prather explains that technology is only one factor of the complex issue.

Dr. Amy Licis details recent observations regarding potential underlying neurobiological reasons for sleep disturbance in pediatric patients with ADHD or autism.

Investigators show a novel risk score helped define more than a dozen metabolites associated with the chronic sleep condition.

While young adults may be resistant to drinking interventions, improving sleep behavior can indirectly reduce hazardous drinking.

Mark Blumberg, MD, discusses his laboratory's particular interest in early REM sleep movement, and its potential impact on neurological disorders.

There are still many aspects of sleep health that need to be understood, especially in relation to the COVID-19 pandemic.